<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0217513</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1037</journal-id>
<journal-id journal-id-type="nlm-ta">Biochim Biophys Acta</journal-id>
<journal-id journal-id-type="iso-abbrev">Biochim. Biophys. Acta</journal-id>
<journal-title-group>
<journal-title>Biochimica et biophysica acta</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-3002</issn>
<issn pub-type="epub">1878-2434</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29627384</article-id>
<article-id pub-id-type="pmc">5953829</article-id>
<article-id pub-id-type="doi">10.1016/j.bbalip.2018.03.010</article-id>
<article-id pub-id-type="manuscript">NIHMS957855</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Can modulators of apolipoproteinB biogenesis serve as an alternate target for cholesterol-lowering drugs?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Doonan</surname>
<given-names>Lynley M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fisher</surname>
<given-names>Edward A.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brodsky</surname>
<given-names>Jeffrey L.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260</aff>
<aff id="A2">
<label>2</label>Departments of Medicine (Cardiology) and Cell Biology and the Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, New York, NY 10016</aff>
<author-notes>
<corresp id="FN1">Corresponding author: Jeffrey L. Brodsky, Ph.D., A320 Langley Hall, Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260; Tel: 412-624-4831; FAX: 412-624-4759; <email>jbrodsky@pitt.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>6</day>
<month>4</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>06</day>
<month>4</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>7</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>7</month>
<year>2019</year>
</pub-date>
<volume>1863</volume>
<issue>7</issue>
<fpage>762</fpage>
<lpage>771</lpage>
<!--elocation-id from pubmed: 10.1016/j.bbalip.2018.03.010-->
<abstract>
<title>SUMMARY</title>
<p id="P3">Understanding the molecular defects underlying cardiovascular disease is necessary for the development of therapeutics. The most common method to lower circulating lipids, which reduces the incidence of cardiovascular disease, is statins, but other drugs are now entering the clinic, some of which have been approved. Nevertheless, patients cannot tolerate some of these therapeutics, the drugs are costly, or the treatments are approved for only rare forms of disease. Efforts to find alternative treatments have focused on other factors, such as apolipoproteinB (apoB), which transports cholesterol in the blood stream. The levels of apoB are regulated by endoplasmic reticulum (ER) associated degradation as well as by a post ER degradation pathway in model systems, and we suggest that these events provide novel therapeutic targets. We discuss first how cardiovascular disease arises and how cholesterol is regulated, and then summarize the mechanisms of action of existing treatments for cardiovascular disease. We then review the apoB biosynthetic pathway, focusing on steps that might be amenable to therapeutic interventions.</p>
</abstract>
<kwd-group>
<kwd>Cardiovascular Disease</kwd>
<kwd>Cholesterol</kwd>
<kwd>ApolipoproteinB</kwd>
<kwd>Very Low Density Lipoprotein (VLDL)</kwd>
<kwd>Endoplasmic Reticulum Associated Degradation (ERAD)</kwd>
<kwd>Autophagy</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>